Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR-TKI benefit in stage IV lung adenocarcinoma
{{output}}
Background: Outcomes in stage IV lung adenocarcinoma (LUAD) remain heterogeneous despite established genomic and immune biomarkers. We evaluated the prognostic and predictive value of soluble interleukin-2 receptor (sCD25), a mar... ...
